Abstract
OBJECTIVE—The purpose of this study was to assess incidence of and risk factors for recurrent cardiovascular disease (CVD) in type 2 diabetes.RESEARCH DESIGN AND METHODS—We estimated the incidence of recurrent cardiovascular events in type 2 diabetic patients, aged 40–97 years, followed by a network of diabetes clinics. The analysis was conducted separately for 2,788 patients with CVD at enrollment (cohort A) and for 844 patients developing the first episode during the observation period (cohort B).RESULTS—During 4 years of follow-up, in cohort A the age-adjusted incidence of a recurrent event (per 1,000 person-years) was 72.7 (95% CI 58.3–87.1) in men and 32.5 (21.2–43.7) in women, whereas in cohort B it was 40.1 (17.4–62.9) in men and 22.4 (12.9–32.0) in women. After controls were included for potential predictors (familial CVD, obesity, smoking, diabetes duration, glycemic control, microvascular complications, geographic area, and antihypertensive and lipid-lowering treatment), male sex, older age, and insulin use were significant independent risk predictors (cohort A) and serum triglyceride levels ≥1.69 mmol/l emerged as the only metabolic (negative) prognostic factor (cohort B). In both cohorts, a prior CVD episode, especially myocardial infarction, was by far the strongest predictor of recurrent CVD.CONCLUSIONS—Approximately 6% of unselected diabetic patients in secondary prevention develop recurrent major CVD every year. Those with long-standing previous CVD show a higher incidence of recurrence. Male sex, age, high triglyceride levels, and insulin use are additional predictors of recurrence.
Topics

No keywords indexed for this article. Browse by subject →

References
24
[1]
Abbott RD, Donahue RP, Kannel WB, Wilson PW: The impact of diabetes on survival following myocardial infarction in men vs. women: the Framingham Study. JAMA 260: 3456–3460, 1988 10.1001/jama.260.23.3456
[2]
Miettinen H, Lehto S, Salomaa VV, Mähönen M, Niemelä M, Haffner SM, Pyörälä K, Tuomilheto J: Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 21:69–75, 1998 10.2337/diacare.21.1.69
[3]
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality form coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234, 1998 10.1056/nejm199807233390404
[4]
Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, PROactive Investigators: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 49:1772–1780, 2007 10.1016/j.jacc.2006.12.048
[5]
The DAI Study Group: Prevalence of coronary heart disease in a cohort of type 2 diabetic patients in Italy: the DAI study. Diabet Med 21:738–745, 2004 10.1111/j.1464-5491.2004.01230.x
[6]
Harris MI, Hadden WC, Knowler WC, Bennett PH: International criteria for the diagnosis of diabetes and impaired glucose tolerance. Diabetes Care 8:562–567, 1985 10.2337/diacare.8.6.562
[8]
Strandberg TE, Pitkala KH, Berglind S Nieminen MS, Tilvis RS: Multifactorial intervention to prevent recurrent cardiovascular events in patients 75 years or older: the Drugs and Evidence-Based Medicine in the Elderly (DEBATE) study: a randomized, controlled trial. Am Heart J 152:585–592, 2006 10.1016/j.ahj.2006.02.006
[9]
Lichtman JH, Krumholz HM, Wang Y, Radford MJ, Brass LM: Risk and predictors of stroke after myocardial infarction among the elderly: results from Cooperative Cardiovascular Project. Circulation 105:1082–1087, 2002 10.1161/hc0902.104708
[10]
Croxson SC, Burden AC, Bodington M, Botha JL: The prevalence of diabetes in elderly people. Diabet Med 8:28–31, 1991 10.1111/j.1464-5491.1991.tb01512.x
[11]
Murabito JM, Evans JC, Larson MG, Levy D: Prognosis after the onset of coronary heart disease: an investigation of differences in outcome between the sexes according to initial coronary disease presentation. Circulation 88:2548–2555, 1993 10.1161/01.cir.88.6.2548
[12]
Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, Spila-Alegiani S, Turco S, Velussi M, Ferrannini E: Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 30:1241–1247, 2007 10.2337/dc06-2558
[13]
Giorda CB, Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, Alegiani SS, Raschetti R, Velussi M, Ferrannini E, DAI Study Group: Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke 38:1154–1160, 2007 10.1161/01.str.0000260100.71665.2f
[14]
Stone PH, Thompson B, Anderson HV, Kronenberg MW, Gibson RS, Rogers WJ, Diver DJ, Thèroux P, Warnica JW, Nasmith JB, Kells C, Kleiman N, McCabe CH, Schactman M, Knatterud GL, Braunwald E: Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: the TIMI III registry. JAMA 275:1104–1112, 1996 10.1001/jama.1996.03530380046030
[15]
Frishman WH, Gomberg-Maitland M, Hirsch H, Catanese J, Furia-Palazzo S, Mueller H, Steingart R, Forman S: Differences between male and female patients with regard to baseline demographics and clinical outcomes in the Asymptomatic Cardiac Ischemia Pilot (ACIP) trial. Clin Cardiol 21:184–190, 1998 10.1002/clc.4960210310
[16]
Wang S-L, Head J, Stevens L, Fuller JH, WHO Multinational Study Group: Excess mortality and its relation to hypertension and proteinuria in diabetic patients: the WHO multinational study of vascular disease in diabetes. Diabetes Care 19:305–312, 1996 10.2337/diacare.19.4.305
[17]
Rosengren A, Wilhelmsen L, Hagman M, Wedel H: Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged med: a 16-year follow-up of the Primary Prevention Study, Göteborg, Sweden. J Intern Med 244:495–505, 1998 10.1111/j.1365-2796.1998.00394.x
[18]
Lampe FC, Whincup PH, Wannamethee SG, Shaper AG, Walker M, Ebrahim S: The natural history of prevalent ischaemic heart disease in the middle-aged men. Eur Heart J 21:1052–1062, 2000 10.1053/euhj.1999.1866
[19]
Kronmal RA, Barzilay JI, Smith NL, Psaty BM, Kuller LH, Burke GL, Furberg C: Mortality in pharmacologically treated older adults with diabetes: the Cardiovascular Health Study, 1989–2001. PLoS Med 3:e424, 2006 10.1371/journal.pmed.0030400
[20]
Kronmal RA, Barzilay JI, Tracy RP, Savage PJ, Orchard TJ, Burke GL: The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort. J Clin Endocrinol Metab 89:2852–2858, 2004 10.1210/jc.2003-031822
[21]
Delgado-Rodriguez M, Llorca J Bias. J: Epidemiol Community Health 58:635–641, 2004 10.1136/jech.2003.008466
[22]
Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, Rochon PA, Anderson GM: Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 330:960–962, 2005 10.1136/bmj.330.7497.960
[24]
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman R: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412, 2000 10.1136/bmj.321.7258.405